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Abstract. 
 
c-src
 
 deletion in mice leads to osteopetrosis
as a result of reduced bone resorption due to an alter-
ation of the osteoclast. We report that deletion/reduc-
tion of Src expression enhances osteoblast differentia-
tion and bone formation, contributing to the increase in
bone mass. Bone histomorphometry showed that bone
formation was increased in Src null compared with
wild-type mice. In vitro, alkaline phosphatase (ALP)
activity and nodule mineralization were increased in
primary calvarial cells and in SV40-immortalized osteo-
 
blasts from Src
 
2
 
/
 
2
 
 relative to Src
 
1
 
/
 
1
 
 mice. Src-antisense
oligodeoxynucleotides (AS-src) reduced Src levels by
 
z
 
60% and caused a similar increase in ALP activity
and nodule mineralization in primary osteoblasts in
 
vitro. Reduction in cell proliferation was observed
in primary and immortalized Src
 
2
 
/
 
2
 
 osteoblasts and in
normal osteoblasts incubated with the AS-src. Semi-
quantitative reverse transcriptase-PCR revealed upreg-
ulation of ALP, Osf2/Cbfa1 transcription factor, PTH/
PTHrP receptor, osteocalcin, and pro-alpha 2(I) col-
lagen in Src-deﬁcient osteoblasts. The expression of the
bone matrix protein osteopontin remained unchanged.
Based on these results, we conclude that the reduction
of Src expression not only inhibits bone resorption, but
also stimulates osteoblast differentiation and bone for-
mation, suggesting that the osteogenic cells may con-
tribute to the development of the osteopetrotic pheno-
type in Src-deﬁcient mice.
Key words: osteopetrosis • Src • osteoblast • differen-
tiation • bone formation
 
Introduction
 
Targeted disruption of the 
 
c-src
 
 gene in mice has been
demonstrated to cause osteopetrosis (Soriano et al.,
1991a). Although the sarcoma (Src)
 
1
 
 gene product is ubiq-
uitous and highly expressed in several cell types, including
platelets (Golden et al., 1986) and neurons (Pyper and
Bolen, 1990), these mice develop only a bone phenotype
(Soriano et al., 1991a). Therefore, much interest has been
focused on the role of this gene in bone cells.
 
The Src family of nonreceptor tyrosine kinases consists of
10 proteins that contribute to many regulated events in cells
(Thomas and Brugge, 1997). These proteins share a high ho-
 
mology and consist of a unique NH
 
2
 
-terminal domain con-
taining a short SH4 motif for myristoylation and palmitoyla-
tion, a SH3 and a SH2 domain involved in protein–protein
interactions, and a COOH-terminal SH1 tyrosine kinase do-
main (Resh, 1994; Wenqing et al., 1997). Several substrates
have been demonstrated to be tyrosine phorphorylated by
Src, including transmembrane tyrosine kinase receptors
(platelet-derived growth factor [PDGF], epidermal growth
factor [EGF], and macrophage colony stimulating factor
[CSF]-1), focal adhesion associated kinases (focal adhesion
kinase, proline-rich tyrosine kinase2, Cdk-activating kinase),
adhesion molecules (vinculin), and soluble enzymes (eno-
lase, phosphoglyceromutase, and lactate dehydrogenase)
(Hunter and Cooper, 1985; Parson and Parson, 1997).
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The recognized defect in Src
 
2
 
/
 
2
 
 mice consists in the al-
teration of the bone resorbing cell function. Increased
numbers of osteoclasts at the bone surface, which are inac-
tive and lack a ruffled border, are remarkable features of
this bone phenotype (Boyce et al., 1992; Horne et al., 1992;
Lowe et al., 1993). Impairment of osteoclastic bone resorp-
tion leads to decreased bone remodeling, which results in
small size, failure in incisor eruption, thickened growth
plate, poorly developed cortex, persistence of endochon-
dral primary spongiosa with widening and extension of tra-
becular bone in the distal methaphysis and diaphysis, and
reduced bone marrow tissue that fills the very little re-
maining space of the bone cavity (Soriano et al., 1991a).
Osteoclast differentiation and bone resorption are also
dependent on cells of the osteoblast lineage (Rodan and
Martin, 1981; Suda et al., 1997). However, Lowe et al.
(1993) demonstrated that osteoblasts derived from 
 
c-src
 
knockout mice successfully contributed to normal osteo-
clast differentiation and showed unremarkable morpho-
logical features relative to wild-type mice. This lead to the
conclusion that the inherited defect is exclusively with ma-
ture osteoclasts and is autonomous from the bone marrow
microenvironment. However, a detailed molecular analy-
sis of osteoblast function has not been performed. A re-
cent examination of the skeletal phenotype in older Src
 
2
 
/
 
2
 
mice has indicated that bone mass continues to increase
with age, suggesting a continued imbalance between bone
resorption and formation (Amling et al., 2000). Therefore,
this present study was aimed at determining whether in-
hibition of Src expression in vivo or in vitro lead to al-
terations in osteoblast functions and bone formation, a
feature which could contribute to the osteopetrotic phe-
notype, together with the decreased bone resorption.
 
Materials and Methods
 
Materials
 
DME, FCS, penicillin, streptomycin, and trypsin were from GIBCO BRL.
Sterile plasticware was from Becton Dickinson. Anti-Src and anti-actin
pAbs and HRP-conjugated secondary antibodies were from Santa Cruz
Biotechnology, Inc. Antibody L-123 to osteopontin (Fisher et al., 1995) was
donated by Dr. Larry Fisher (Craniofacial and Skeletal Diseases Branch,
National Institute of Dental Research, National Institutes of Health, Be-
thesda, MD). Synthetic totally phosphorothioated oligodeoxynucleotide
(ODN) sequences (Tanaka et al., 1996) were as follows: antisense (AS-src),
5
 
9
 
-GGGCTTGCTCTTGTTGCTGCCCAT-3
 
9
 
 and sense (S-src), 5
 
9
 
-
ATGGGCAGCAACAAGAGCAAGCCC-3
 
9
 
. ODNs were purchased
from M-Medical. Enhanced chemiluminescence kit was from Amersham
Pharmacia Biotech. Primers and reagents for reverse transcriptase (RT)-
PCR were from Promega. Benzoyl peroxide was from Polyscience Inc. All
other reagents were of the purest grade from Sigma-Aldrich.
 
Histology and Histomorphometry
 
3- and 10-wk-old Src
 
1
 
/
 
1
 
 and Src
 
2
 
/
 
2
 
 mice were injected with calcein (20 mg/
kg body weight) followed by the same dose of demeclocycline at a 5-d in-
terval. Animals were killed 2 d after the second injection and tibiae were
dissected out, fixed in 3.7% formaldehyde in PBS, and embedded in meth-
ylmethacrylate by a procedure modified from Baron et al. (1983). Specifi-
cally, bones were dehydrated in graded acetone for 1 h in each of 70%,
90%, and twice in 100% acetone then infiltrated and embedded in 80%
activated methylmethacrylate (Jowsey et al., 1965), 20% dibutylphthalate,
and 4% benzoyl peroxide. 5-
 
m
 
m sections were stained with toluidine blue
or unstained, with a coverslip on top, for analysis of fluorochrome labels.
Histomorphometric analysis of the secondary spongiosa was carried out
according to standard procedures (Parfitt et al., 1987) using the Os-
 
teomeasure system (OsteoMetrics, Inc.) in a region 200 
 
m
 
m below the
chondro–osseous junction to the diaphysis.
 
Osteoblast Cultures
 
Primary cultures of calvarial osteoblasts were prepared by a modification
of the sequential collagenase/trypsin digestion method (Robey and Ter-
mine, 1985). In brief, calvaria were removed from 7–9-d-old CD1 mice or
B6, 129
 
tm/Sor
 
 Src
 
1
 
/
 
1
 
 and Src
 
2
 
/
 
2
 
 mice, cleaned free from soft tissue, and di-
gested with 1 mg/ml 
 
Clostridium histolyticum
 
 type IV collagenase and
0.025% trypsin for 20 min at 37
 
8
 
C in HBSS with gentle agitation. The pro-
cedure was repeated three times and cells from the second and third diges-
tions were plated in petri dishes and grown to confluence in DME supple-
mented with antibiotics and 10% FCS. At confluence, cells were
trypsinized by the standard procedure and plated in wells for experiments.
The cells obtained with this method were positive for alkaline phos-
phatase (ALP) activity and expression of the osteoblast markers, parathy-
roid hormone/parathyroid hormone–related peptide (PTH/PTHrP) re-
ceptor and Osf2/Cbfa1 transcription factor, and of bone matrix proteins,
osteopontin and bone sialoprotein II.
 
Immortalized Osteoblasts
 
Permanent osteoblast cell lines were prepared from Src
 
1
 
/
 
1
 
 and Src
 
2
 
/
 
2
 
mice (B6, 129
 
tm/Sor
 
) and immortalized by infection with the SV40 virus, ac-
cording to Soriano et al. (1991b). Cells were grown in DME supplemented
with 10% FCS and antibiotics in standard culture conditions. Cells were
fed twice a week, trypsinized at confluence, and split 1:5.
 
ODNs
 
AS-src and S-src ODNs were diluted in culture medium in 100-
 
m
 
M stock
solutions and stored in aliquots at 
 
2
 
20
 
8
 
C until used. They were then di-
luted to the final concentration in medium and administered to the cells
for 24 h–3 wk, according to the experimental design. The most effective
concentration was 1 
 
m
 
M. Lower concentrations of AS-src had little effect,
whereas concentrations 
 
.
 
1 
 
m
 
M often resulted in nonspecific changes,
which were also observed in S-src–treated cultures. Experiments in which
osteoblasts were incubated with a mixture of ODNs and 5 
 
m
 
g/ml of the up-
take enhancer lipofectamine resulted in effects similar to cultures incu-
bated with the ODNs alone. Therefore, all the experiments illustrated be-
low were performed at 1 
 
m
 
M of both AS-src and S-src ODNs without
uptake enhancer.
 
Immunoblotting
 
Cells were lysed in ice-cold 0.1% SDS containing protease inhibitors and 1
mM sodium orthovanadate, and stored at 
 
2
 
80
 
8
 
C until used. Protein con-
tent was measured using the Bradford method, and then 25–60 
 
m
 
g of cell
protein in reducing sample buffer was subjected to 10% SDS-PAGE. Pro-
teins were then transferred to nitrocellulose filter papers and probed with
the primary antibody overnight at 4
 
8
 
C, followed by the secondary anti-
body for 1 h at room temperature. Bands were revealed by enhanced
chemiluminescence detection.
 
RT-PCR
 
RNA was prepared from osteoblasts using the acid phenol technique. For
RT-PCR, 1 
 
m
 
g/ml of total RNA was reverse-transcribed using Moloney-
murine leukemia virus RT and the equivalent of 0.1 
 
m
 
g was added to PCR
reactions. These were carried out in a final volume of 20 
 
m
 
l buffer contain-
ing 200 
 
m
 
M of deoxynucleoside triphosphates, 1.5 mM MgCl
 
2
 
, 10 pM of
each primer, and 1 U of 
 
Thermus aquaticus
 
 DNA polymerase. PCR condi-
tions and primer pairs used are listed in Table I. For quantitative analysis,
primers for the housekeeping gene glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) were used along with the primers for the gene being an-
alyzed. 10–30 
 
m
 
l of the PCR-amplified products were analyzed on 1–1.5%
agarose gels containing ethidium bromide.
 
DNA Staining
 
To stain the DNA and morphologically evaluate apoptosis, cells were
fixed in Carnoy’s fixative (methanol/glacial acetic acid, 3:1), incubated for
30 min in 0.5 
 
m
 
g/ml 
 
bis
 
-benzimide, which specifically binds the adenine-
thymine regions of the nucleic acid, rinsed twice in distilled water,
mounted in glycerol/PBS, 1:1, and observed by conventional epifluores- 
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cence microscopy. The apoptotic nuclei were then enumerated and ex-
pressed as mean percentage of the total number of nuclei.
 
Cell Proliferation
 
Osteoblasts were plated in 24-well multiplates and grown to 70% conflu-
ence. Cells were then treated with the test compounds for 48 h and incu-
bated for the final 4 h with 1 
 
m
 
Ci/ml [
 
3
 
H]thymidine (specific activity 14.3 Ci/
mmol). At the end of incubation cells were solubilized in 1 ml of 1% SDS to
which 10 
 
m
 
l of 10 mg/ml BSA was added as a carrier protein, and precipi-
tated by addition of 100 
 
m
 
l of 100% TCA. After incubation for 30 min at
4
 
8
 
C, the TCA-precipitable material was pelleted by centrifugation at 955 
 
g
 
,
redissolved in 500 
 
m
 
l of 1% SDS, and counted in a scintillation spectropho-
tometer after addition of 500 
 
m
 
l of water and 9 ml of scintillation fluid.
 
ALP Activity
 
ALP activity was evaluated histochemically and biochemically, using the
Sigma kits n.85 and 104-LS, respectively, according to the manufacturer’s
instruction (Sigma-Aldrich).
 
Nodule Mineralization
 
Osteoblasts were plated in 24-well multiplates and grown until confluent.
Media were then replaced with mineralizing media (DME supplemented
with 10% FCS, 10 mM 
 
b
 
-glycerophosphate, 50 
 
m
 
g/ml ascorbic acid, with
or without 10
 
2
 
7 
 
M dexamethasone) containing, where indicated, 1 
 
m
 
M
AS-Src or S-Src, and cells were cultured for an additional 3 wk. Media
were replaced with fresh media containing the test compounds every 3 d.
At the end of incubation, mineralization was detected with von Kossa
staining. Quantitative analysis was performed by scanning densitometry
on computer-assisted acquired images as described below.
 
Densitometric Analysis
 
Scanning densitometry of the areas of interest was performed using the
Molecular Analyst software for the model 670 scanning densitometer
(Bio-Rad Laboratories) to obtain the arbitrary density units. Normaliza-
tion for immunoblotting and RT-PCR was performed using as internal
controls the reference genes 
 
b
 
-actin and GAPDH, respectively. The
“gene of interest/reference gene” density ratio was then computed and
represented in graphs.
 
Statistics
 
Data are expressed as mean percentage 
 
6 
 
SEM of at least three independent
experiments. Statistical significance was computed by the unpaired Student’s
 
t
 
 test. A
 
 P 
 
value 
 
, 
 
0.05 was conventionally considered statistically significant.
 
Results
 
In Vivo Histomorphometry
 
Histomorphometric analysis of 3- and 10-wk-old Src
 
2
 
/
 
2
 
and Src
 
1
 
/
 
1
 
 mice was carried out to determine whether
bone formation was increased in the absence of Src in vivo
(Fig. 1). As observed previously, both trabecular bone vol-
ume (BV/TV) and osteoclast surface (OcS/BS) were sig-
nificantly increased in Src
 
2
 
/
 
2
 
 mice. Bone formation was
assessed by examining fluorochrome labels incorporated
during mineralization in the same mice and an 
 
z
 
50% in-
crease in bone formation rate (BFR/BS) was observed at
both 3 and 10 wk, which, for the most part, was due to an
increase in mineralizing surface (MS/BS) rather than a
change in mineral appositional rate (MAR). In contrast,
the increase in osteoblast surface, expressed as a ratio of
bone surface, in Src
 
2
 
/
 
2
 
 mice was only significantly ele-
vated at 3 wk.
Since BV/TV and trabecular number (TbN) are both
dramatically increased in osteopetrotic Src
 
2
 
/
 
2
 
 mice, and
since ObS/BS is expressed as a ratio of osteoblast surface
to total bone surface, any effect of Src deficiency on the
number of osteoblasts may be masked by the large extent
of bone surface in Src
 
2
 
/
 
2
 
 mice (trabecular bone surface
was 
 
z
 
3.4 times that of wild-type mice). To take this
change into account, the total number of osteoblasts was
also assessed by measuring osteoblast number relative to
the area of secondary spongiosa (ObN/TAr), as well as the
total bone surface lined with osteoblasts (ObPm). Indeed,
when the increased trabecular bone surface is taken into
account, we found that the total number of osteoblasts, in-
dicated by both ObN/TAr and ObPm was significantly in-
creased in Src
 
2
 
/
 
2
 
 mice, about twofold at both 3 and 10 wk.
As expected, osteoclast number and total osteoclast sur-
face were both dramatically increased in Src
 
2
 
/
 
2
 
 mice.
Thus, Src
 
2
 
/
 
2
 
 mice exhibit not only a cell autonomous de-
fect in bone resorption (Soriano et al., 1991a; Lowe et al.,
1993), but also a dramatic increase in osteoblast numbers
and bone formation, changes that would contribute signifi-
cantly to the osteopetrotic phenotype and explain the con-
tinued increase in bone mass in the knockout mice (Am-
ling et al., 2000).
 
Cell Culture Study
 
To determine whether the altered osteoblast phenotype
was cell autonomous, primary calvarial cells harvested
from Src null mice were cultured and analyzed for ALP
expression and nodule mineralization (Fig. 2). We found
that the number of ALP-positive cells was approximately
fourfold higher (Fig. 2 a) and the rate of mineralized nod-
 
Table I. Primers and Conditions Used for RT-PCR
 
Gene Primers PCR conditions bp References
ALP
Fw: 5
 
9
 
-GCCCTCTCCAAGACATATA-3
 
9
 
Rv: 5
 
9
 
-CCATGATCACGTCGATATCC-3
 
9
 
30 cycles: 95
 
8
 
C 1 min, 
55
 
8
 
C 2 min, 72
 
8
 
C 1 min 372 Qu et al., 1998
PTH/PTHrP receptor Fw: 5
 
9
 
-CGCGGCCCTAGGCGGT-39
Rv: 59-TAGTTGGCCCACGTCC-39
30 cycles: 958C 1 min, 
618C 2 min, 728C 1 min
520 Gene Bank accession number X78936
Osf2/Cbfa1 Fw: 59-CCGCACGACAACCGCACCAT-39
Rv: 59-CGCTCCGGCCCACAAATCTC-39
30 cycles: 948C 30 s, 
608C 30 s, 728C 30 s
289 Komori et al., 1997
Osteocalcin Fw: 59-AAGCAGGAGGGCAATAAGGT-39
Rv: 59-AGCTGCTGTGACATCCATAC-39
35 cycle: 958C 1 min, 
608C 2 min, 728C 1 min
292 Gene Bank accession number L24429
COL1A2 Fw: 59- GCAATCGGGATCAGTACGAA-39
Rv: 59- CTTTCACGCCTTTGAAGCCA-39
30 cycles: 958C 1 min,
57.38C 2 min, 728C 1 min
484 Gene Bank accession number X58251
Osteopontin Fw: 59-TCACCATTCGGATGAGTCTG-39
Rv: 59-ACTTGTGGCTCTGATGTTCC-39
30 cycles: 958C 1 min, 
558C 2 min, 728C 1 min
437 Chackalaparampil et al., 1996
GAPDH
Fw: 59-CACCATGGAGAAGGCCGGGG-39
Rv: 59-GACGGACACATTGGGGGTAG-39
25 cycle:, 958 1 min, 
558C 2 min, 728C 1 min 418 Qu et al., 1998
bp, Base pairs; Fw, forward; Rv, reverse.The Journal of Cell Biology, Volume 151, 2000 314
ule formation was significantly increased (approximately
twofold, Fig 2 b) in Src null primary osteoblasts relative to
wild-type cells. No morphological changes were observed
in Src2/2 osteoblasts, and DNA staining by bis-benzimide
revealed the same numbers of apoptotic cells as the wild-
type cells (Src1/1, 8.4 6 0.7%; Src2/2, 7.7 6 0.8% of the to-
tal number of nuclei; n 5 3; P 5 0.6). Therefore, these re-
sults suggest that the increased osteoblastic function
observed in vivo in Src2/2 mice is cell autonomous.
We then used SV40-immortalized osteoblasts from Src2/2
or Src1/1 animals to further investigate this possibility.
As expected, expression of the SV40 large T antigen did
not modify the pattern of Src expression, with no protein
in Src2/2 cells, whereas normal protein levels were ob-
served in Src1/1 osteoblasts (Fig. 3 a). These immortalized
osteoblasts showed low ALP activity in standard culture
conditions. However, ALP activity spontaneously in-
creased in long-term cultures, with greater activity ob-
served in Src2/2 versus Src1/1 cells at any time point (Fig. 3
b). In addition, ALP activity was stimulated by treatment
with the differentiating agent dexamethasone, with, once
again, a higher level of ALP in Src2/2 relative to Src1/1
cells (Fig. 3 b).
In contrast to primary cultures, immortalized Src1/1
cells failed to form mineralized nodules in vitro, indepen-
dent of time in culture and treatment with dexamethasone
(Fig. 3 c). In contrast, Src2/2 cells formed a few small min-
eralized nodules even in the absence of dexamethasone,
whereas in the presence of dexamethasone these cultures
underwent macroscopic nodule mineralization clearly visi-
ble by week 3 of culture (Fig. 3 c).
Taken together these findings suggest that Src deletion
favors osteoblast differentiation and function in vitro and
in vivo and in a cell autonomous manner. Therefore, Src
may play a negative role in osteoblast differentiation and/
or function. To test this hypothesis and elucidate whether
the increased osteoblast function was directly related to
Src deletion, we reduced Src expression in normal calva-
Figure 1. Histomorphometric
analysis of tibiae from 3- and 10-
wk-old Src1/1 and Src2/2 mice.
Samples from 3 and 10-wk-old
Src1/1 and Src2/2 mice were
fixed, embedded in methyl-
methacrylate, and evaluated for
histomorphometric analysis as
described in the Materials and
Methods. All values are mean 6
SEM from at least three animals
for each category. Src1/1; Src2/2;
*P , 0.05, **P , 0.01 and
***P , 0.001 versus Src1/1
mice.
Figure 2. Src-deficient osteoblast phenotype. Primary calvarial
osteoblasts were harvested from B6, 129tm/sor mice, as described
in Materials and Methods, and cultured for detection of ALP ac-
tivity and nodule mineralization. (a) 90% confluent osteoblasts
were cultured for 1 wk, fixed, and stained histochemically to de-
tect ALP activity using the Sigma kit n. 85. ALP-positive cells
were counted and converted into a percentage versus the total
number of cells. Data are the mean 6 SEM of three independent
experiments. ***P , 0.001 versus Src1/1. (b) 90% confluent os-
teoblasts were cultured for 3 wk in the presence of ascorbic acid
and b-glycerophosphate, as described in Materials and Methods.
Cultures were then fixed and mineralized (dark) nodules were
detected by von Kossa staining. Quantitative analysis was per-
formed by scanning densitometry, as described in Materials and
Methods, and data from three independent experiments were ex-
pressed as arbitrary densitometric units (mean 6 SEM). **P ,
0.01 versus Src1/1.Marzia et al. Src Affects Osteoblast Differentiation and Function 315
rial osteoblasts by the use of AS-src shown previously to
inhibit Src synthesis in osteoclasts and affecting Src-
dependent functions (Tanaka et al., 1996). In osteoblasts
treated for 24 h with 1 mM AS-src or with the control sense
(S-src) sequence, we found that AS-src reduced Src pro-
tein level by z60%, whereas the control oligonucleotide
S-src was inactive (Fig. 4).
Using this assay, we determined whether treatment with
the AS-src would result in alterations of the osteoblast
proliferation/differentiation pattern. The incorporation of
[3H]thymidine into the TCA-precipitable material derived
from osteoblasts exposed to the ODNs for 48 h was signif-
icantly decreased by AS-src, but not by S-src, producing a
significant 40% inhibition of cell proliferation (Fig. 5 a). A
similar reduction of [3H]thymidine incorporation was ob-
served in primary (Fig. 5 b) as well as in SV40-immortal-
ized (Fig. 5 c) Src2/2 versus Src1/1 osteoblasts.
The effect of a reduction in Src expression could be to
promote differentiation, which would only secondarily de-
crease cell proliferation. To determine whether inhibition
of Src expression could favor osteoblast differentiation, we
analyzed specific markers of the osteoblast phenotype.
Treatment of osteoblasts with AS-src increased the num-
ber of ALP-positive osteogenic cells, whereas S-src was
again inactive relative to control (Fig. 6 a). Further confir-
mation of enhancement of ALP activity was demonstrated
by the quantitative analyses, using histochemical (Fig. 6 b)
and biochemical (Fig. 6 c) assays, which showed a greater
than twofold increase of the enzyme activity in AS-src-
versus S-src–treated and control cultures.
We then measured nodule mineralization in the pres-
ence of the ODNs, which was added repetitively to the
medium during the entire length of the culture period (see
Materials and Methods). Fig. 7 shows that AS-src, but not
S-src, was able to stimulate nodule mineralization over a
Figure 3. Osteoblast phenotype
in Src1/1 and Src2/2 immortal-
ized cells. (a) Src protein expres-
sion in immortalized osteoblasts.
Confluent monolayers were lysed
and 60 mg of total cell protein
was electrophoresed in a 10%
SDS-PAGE, blotted to nitrocel-
lulose filter paper, and probed
with Src pAb (diluted 1:250) at
48C overnight, followed by the
HRP-conjugated secondary an-
tibody (diluted 1:5,000) at 378C
for 1 h. The filter was stripped
and reprobed with anti-actin
pAb (diluted 1:250). Bands were
detected by ECL. This evalua-
tion was repeated three times
with similar results. (b) 90%
confluent Src1/1 and Src2/2 im-
mortalized osteoblasts were cul-
tured for the indicated times and
subjected to determination of
ALP, as described in the legend
to Fig. 2. Cultures were treated
with or without 1027 M dexam-
ethasone (Dex) for the entire
time frame. Positive nodules are
evident as dark spots. This ex-
periment was repeated three
times with similar results. (c)
90% confluent Src1/1 and Src2/2
immortalized osteoblasts were
cultured for 3 wk in the presence
of ascorbic acid and b-glycerophosphate, as described in the Materials and Methods and with or without 1027 M Dex for the entire time
frame. Cultures were then fixed and subjected to von Kossa staining for the detection of nodule mineralization (dark areas). Quantita-
tive analysis was performed by scanning densitometry, as described in the Materials and Methods, and data from three independent ex-
periments were expressed as arbitrary densitometric units (mean 6 SEM). ***P , 0.001 versus Src1/1; ND, non detectable.
Figure 4. Immunoblotting analysis
of Src expression in calvarial osteo-
blasts. Confluent calvarial osteo-
blasts from CD1 mice were treated
with 1 mM AS-src or S-src for 24 h.
Cells were lysed, subjected to SDS-
PAGE, and immunoblotted for Src
and actin, as described in the legend
to Fig. 3. Bands were detected by
ECL. Band densitometric analysis
was performed as described in the
Materials and Methods. The Src/ac-
tin ratio for each treatment was
computed. Similar results were observed in three independent
experiments performed with three different osteoblast prepara-
tions. Statistical significance between AS-src and S-src was
,0.05. C, control; S, S-src ODN; AS, AS-src ODN.The Journal of Cell Biology, Volume 151, 2000 316
period of 3 wk, whether or not cells were cultured in the
presence of dexamethasone (Fig. 7).
We then examined whether Src deficiency affected the
expression of marker genes of the osteoblast phenotype.
For this purpose we performed semiquantitative RT-PCR
using primers for the housekeeping gene GAPDH along
with primers for the gene being analyzed and measured
the relative ratios by densitometry. Fig. 8 shows that the
transcription of ALP was increased by AS-src, but not by S-src. In addition, two other osteoblast markers, the Osf2/
Cbfa1 transcription factor and the PTH/PTHrP receptor,
were similarly transcriptionally upregulated by the AS-src
versus controls and S-src–treated cultures (Fig. 8). Finally,
the matrix proteins osteocalcin (OCN) and pro-alpha 2(I)
collagen (COL1A2) were significantly increased by the
AS-src. Interestingly, similar increases were observed in
primary (Fig. 9) as well as in immortalized (Fig. 10) Src2/2
Figure 5. Osteoblast proliferation. (a) To assess osteoblast pro-
liferation, 70% confluent cultures were treated for 48 h with 1
mM AS-src (AS), 1 mM S-src (S), or left untreated (C). 1 mCi/ml
of [3H]thymidine was added for the last 4 h, then the cells were
lysed, TCA-precipitated, and the radioactivity was measured by a
b-spectrophotometer. Counts per minutes were then converted
to a percentage of control and expressed as average 6 SEM of
three independent experiments. Statistical significance was ,0.05
(*) versus S-src. (b) Primary osteoblasts and (c) immortalized
Src1/1 and Src2/2 osteoblasts were cultured to 70% confluence, 1
mCi/ml of [3H]thymidine was added for 4 h, and cells were pro-
cessed as described in the legend to a. Data are the mean 6 SEM
of three independent experiment. Statistical significance was
,0.01 (**) versus Src1/1.
Figure 6. ALP activity. (a) 90% confluent calvarial osteoblasts
from CD1 mice were treated for 3 d with 1 mM AS-src, 1 mM S-src,
or left untreated. Cells were fixed, stained histochemically for
ALP activity using the Sigma kit n. 85, and observed by conven-
tional light microscopy. (b) The number of ALP-positive cells
was counted and expressed as mean percentage 6 SEM of con-
trol. Data are from three independent experiments. *P , 0.05
versus S-src. (c) Osteoblasts were lysed and ALP activity was
evaluated biochemically using the Sigma kit n. 104-LS and
p-nitrophenyl phosphate were used as substrate. Activity, nor-
malized versus protein content, was then converted as a percent-
age of control. Data are mean 6 SEM of three independent ex-
periments, *P , 0.05 versus S-src. C, control; S, S-src ODN; AS,
AS-src ODN.
Figure 7. Nodule mineralization. Osteoblasts were plated in 24-
well multiplates, grown to 90% confluence, and incubated for 3
wk with ascorbic acid and b-glycerophosphate, as described in
the Materials and Methods, with the addition of 1 mM AS-src or
S-src, with or without 1027 M dexamethasone (Dex). Cultures
were fixed and mineralization (dark areas) was evidenced by the
von Kossa reaction. Quantitative analysis was performed by
scanning densitometry, as described in the Materials and Meth-
ods, and data from three independent experiments are expressed
as arbitrary densitometric units (mean 6 SEM). *P , 0.05 versus
S-src. C, control; S, S-src ODN; AS, AS-src ODN.
Figure 8. Transcriptional regulation of osteoblast genes. 90%
confluent osteoblasts were incubated for 3 d with 1 mM AS-src, 1
mM S-src, or left untreated, and RNA was extracted. 1 mg RNA
was reverse-transcribed and the equivalent of 0.1 mg was sub-
jected to PCR using primer pairs and conditions as described in
the legend to Table I. Densitometric analysis was performed as
described in Materials and Methods, and then the density ratio
between the gene being analyzed and the constitutive gene
GAPDH was computed. Similar results were observed in three
independent experiments, with P , 0.05 for AS-src treated ver-
sus S-src. C, control; S, S-src ODN; AS, AS-src ODN.Marzia et al. Src Affects Osteoblast Differentiation and Function 317
osteoblasts as compared with wild-type cells. In contrast,
the pattern of expression of osteopontin, a bone matrix
sialoprotein that is not osteoblast specific, was not modi-
fied by treatment with AS-src, or in primary, as well as in
immortalized Src2/2 osteoblasts relative to control cell
(Fig. 11).
Discussion
Analysis of osteoblast characteristics in the absence of Src
shows that Src deletion or decreased expression leads to a
marked increase in osteoblast differentiation and bone for-
mation, both in vivo and in vitro. Our in vivo observations
clearly show that besides a continuous increase in bone
mass (Amling et al., 2000), Src2/2 mice exhibit a profound
increase in the number of osteoblasts and in the rate of
bone formation. Primary osteoblasts derived from the cal-
varia of Src2/2 mice show an increased expression of vari-
ous osteoblast markers, decreased proliferation, and an ac-
celerated rate of mineralized nodule formation. Similar
results were obtained with Src2/2 immortalized osteoblast
cell lines and with primary osteoblasts treated with Src-anti-
sense oligonucleotides (AS-Src). Thus, Src deletion leads
to a cell autonomous increase in osteoblast differentiation
and bone formation. These results suggest that under wild-
type conditions Src plays a negative role in these processes.
Despite its heterogeneity, osteopetrosis is defined as an
osteoclast disease. Defects in bone resorption, due to either
defective osteoclast differentiation or to defective function
of the cell, are the cause of all forms of osteopetrosis
(Whyte, 1999). This is in contrast with osteosclerosis, an-
other pathological situation in which bone mass is abnor-
mally high, where it is assumed that the defect is increased
bone formation rather than decreased bone resorption
(Whyte, 1999). However, these two abnormalities in bone
cell differentiation and/or function are not mutually exclu-
sive. So far, little has been done to determine whether, not-
withstanding the osteoclast defects, osteoblasts could also
contribute to the phenotype in some forms of osteopetrosis
(Marks et al., 1989; Shalhoub et al., 1994).
We have recently performed histomorphometric analy-
ses in aging osteopetrotic Src2/2 mice and found that bone
mass continues to increase with time in the absence of Src.
In adult animals, this continued bone formation in the face
of impaired resorption eventually leads to the develop-
ment of extreme osteopetrosis and extramedullary he-
matopoiesis (Amling et al., 2000). However, this study did
Figure 9. Transcriptional regulation of osteoblast genes in pri-
mary Src1/1 and Src2/2 calvarial cells. Src1/1 and Src2/2 primary
osteoblasts were grown to confluence, then RNA was extracted. 1
mg RNA was reverse-transcribed and the equivalent of 0.1 mg was
subjected to PCR using primer pairs and conditions as described
in the legend to Table I. Densitometric analysis was performed as
described in the Materials and Methods, then the density ratio
between the gene being analyzed and the constitutive gene
GAPDH was computed. Similar results were observed in three
independent experiments, with P , 0.05 for Src2/2 versus Src1/1.
Figure 10. Transcriptional regulation of osteoblast genes in im-
mortalized cells. Src1/1 and Src2/2 immortalized osteoblasts were
grown to confluence, then RNA was extracted. 1 mg RNA was
reverse-transcribed and the equivalent of 0.1 mg was subjected to
PCR using primer pairs and conditions as described in the legend
to Table I. Densitometric analysis was performed as described in
the Materials and Methods, and then the density ratio between
the gene being analyzed and the constitutive gene GAPDH was
computed. Similar results were observed in three independent
experiments, with P , 0.05 for Src2/2 versus Src1/1.
Figure 11. Expression of osteopontin. RNA or proteins were ex-
tracted from 90% confluent osteoblasts treated for 3 d with 1 mM
AS-src, 1 mM S-src, or left untreated, or from Src1/1 and Src2/2
primary and immortalized osteoblasts. (a) RT-PCR was per-
formed using the osteopontin (OPN) primer pairs and conditions
as described in the legend to Table I. Densitometric analysis was
performed as described in the Materials and Methods, then the
density ratio between the gene being analyzed and the constitu-
tive gene GAPDH was computed. Similar results were observed
in three independent experiments. Differences are not statisti-
cally significant. (b) 25 mg protein for each sample was electro-
phoresed in a 10% SDS-PAGE, blotted to nitrocellulose filter
paper, and probed with L-123 anti-OPN pAb (diluted 1:250) at
48C overnight, followed by the HRP-conjugated secondary anti-
body (diluted 1:5,000) at 378C for 1 h. Filters were stripped and
reprobed with anti-actin pAb (diluted 1:250). Bands were de-
tected by ECL and densitometric analysis was performed as de-
scribed in the Materials and Methods, and then the OPN/actin
density ratio was computed. Similar results were observed in
three independent experiments. Differences are not statistically
significant. C, control; S, S-src ODN; AS, AS-src ODN.The Journal of Cell Biology, Volume 151, 2000 318
not allow us to determine whether bone formation was at a
normal level, albeit higher than the defective bone resorp-
tion, or whether it was increased above the normal level of
bone formation. Although both situations would lead to a
progressive increase in bone mass, the mechanisms in-
volved are quite distinct. Only in the case where bone for-
mation is higher than normal would the osteoblast poten-
tially be defective. Our dynamic histomorphometric data
clearly show that this is the case in the Src knockout mice.
We observed a marked increase in most parameters of
bone formation in these mutant mice; the bone formation
rate increased to 150% of control values and the osteoblast
number and surface more than doubled. The increased
bone formation in vivo appeared to relate mainly to in-
creased osteoblast number rather than increased matrix
production, which may indicate increased proliferation, ac-
celerated differentiation, or extended lifespan of the osteo-
blast. Thus, not only is bone formation maintained, despite
the decrease in bone resorption known to be present in
these animals (Soriano et al., 1991a; Boyce et al., 1992;
Lowe et al., 1993), but it is actually increased above the
normal level, explaining the progressive increase in bone
mass with time observed in this study and a previous one
(Amling et al., 2000). Most interestingly, our in vitro data
indicate that these changes are cell autonomous, since
Src2/2 cultured primary osteoblasts or immortalized cells
as well as normal osteoblasts treated with AS-Src show a
decrease in proliferation, an increase in the expression of
osteoblast markers, and an increase in the ability to form
mineralized nodules in culture. Since osteoblast apoptosis
is not decreased in Src2/2 primary osteoblasts, it is unlikely
that the osteoblast lifespan is markedly extended in the ab-
sence of Src. Therefore, the increase in the number of os-
teoblasts in vivo is mostly due to increased differentiation.
Whether or not the precursor pool is also induced to prolif-
erate cannot be determined in vivo. However, in vitro Src
deletions lead to decreased cell proliferation. One possibil-
ity is that the early precursor pool is not present in the cul-
tures such that increased differentiation depletes the pool
of preosteoblasts, whereas in vivo the precursor pool could
be continuously replenished at the same rate as cells move
along their differentiation pathway. Therefore, we propose
that the increase in bone mass and bone formation ob-
served in vivo is likely to be the result of a cell-autonomous
enhancement of osteoblast differentiation when Src is de-
leted or when its expression is markedly depressed, as in
our antisense experiments. This suggests that under nor-
mal circumstances, c-Src is a negative regulator of osteo-
blast differentiation and bone formation.
On the basis of the in vivo observations, we attempted
to investigate whether Src could affect the osteoblasts in
vitro. Primary calvarial cells harvested from Src-deficient
mice indeed showed a greater differentiated phenotype
relative to their wild-type counterpart. Our observation
that ALP activity and nodule mineralization in culture was
enhanced in Src2/2 versus Src1/1 strongly supports our hy-
pothesis. Moreover, we further addressed this issue and
analyzed several functional and molecular aspects of os-
teoblast differentiation in two additional osteoblast mod-
els, which were more readily available in culture. These
were (a) calvarial cells harvested previously from Src defi-
cient or wild-type mice and subsequently immortalized in
culture with the SV40 large T antigen, and (b) normal cal-
varial osteoblasts where Src deficiency was achieved by in-
troduction into the cell of a Src-antisense oligonucleotide
(AS-src). As described below, the fact that the same find-
ings were confirmed in all the osteoblast models used in
this study reasonably supports our hypothesis.
Immortalized calvarial cells showed only a weak osteo-
blast phenotype under basal conditions. However, sponta-
neous increase in ALP activity could be seen in long-term
cultures. This is the time when the cells achieve postcon-
fluency, a condition which in our hands represents a stimu-
lus towards osteoblast differentiation (Migliaccio et al.,
1998). In addition, these cells showed normal responsive-
ness to glucocorticoids, which significantly stimulated
ALP activity. A remarkable feature of immortalized Src-
deficient cells was a greater ALP activity, at any time of
culture and treatment with dexamethasone, relative to
normal Src expressing osteoblasts. Higher levels of ALP
activity confirmed the presence of a more differentiated
phenotype, as indicated by the increased matrix mineraliz-
ing ability that could be observed in Src-deficient cells but
not in wild-type immortalized osteoblasts.
Experiments performed with calvarial cells harvested
from normal mice where Src expression was downregu-
lated by the phosphorothioated Src antisense ODN further
confirmed direct involvement of Src in inhibiting osteo-
blast differentiation. AS-src is a complementary nucleic
acid sequence that hybridizes to target the AUG transla-
tional start site of the Src mRNA and form an DNA–RNA
duplex, resulting in the block of translation of the mRNA
into the protein, and activation of RNase H, which de-
stroys the duplex (Alama et al., 1997). This ODN has been
successfully used previously to inhibit Src expression in
mouse osteoclasts (Tanaka et al., 1996). In the same study,
the sense ODN was found to be an appropriate control,
which was also confirmed here. The antisense-specific re-
duction of Src levels demonstrated that the changes ob-
served were indeed due to the antisense sequence-specific
properties of AS-src and not to sequence-independent ef-
fects (Wagner, 1995; Stein, 1997; Bennett, 1998). In this
model, Src expression was not completely inhibited
(z60%). However, enhanced ALP activity and nodule
mineralization were observed relative to the control cul-
tures. Therefore, we believe that increased ALP activity
and nodule mineralization ability reflect conditions directly
related to the deficiency in Src expression in osteoblasts.
Increased ALP activity and mineral deposition were not
the only features indicating a negative role of Src in osteo-
blast differentiation. Osteogenic cells are known to ex-
press various specific markers that distinguish them from
other matrix-forming cells of mesenchyme origin. Among
these, we have selected a few genes that characterize the
osteoblast phenotype and have investigated their Src-
dependent transcriptional regulation. We observed in
Src-deficient osteoblasts, as well as in cells treated with
AS-src, a significant upregulation of ALP, Osf2/Cbfa1
transcription factor, PTH/PTHrP receptor, and matrix
proteins OCN and COL1A2 gene transcripts relative to
normal Src-expressing cells. These markers are considered
highly predictive of the differentiated osteoblast pheno-
type. The transcriptional regulation of these genes is not
well characterized. The ALP gene promoter is known toMarzia et al. Src Affects Osteoblast Differentiation and Function 319
possess a consensus sequence (GGGCGG) for SP1 bind-
ing (Weiss et al., 1988), whereas at least three promoters
have been described in the PTH/PTHrP receptor gene,
one of which, the P2, is also found in mouse (Manen et al.,
1998). In contrast, the promoter of the recently identified
Osf2/Cbfa1 transcription factor (Komori et al., 1997; Ducy
et al., 1997) is still uncharacterized, and only regulation by
bone morphogenetic proteins 4 and 7, vitamin D3, and
Osf2/Cbfa1 itself has been identified so far (Ducy et al.,
1997, 1999; Tsuji et al., 1998). The COL1A2 promoter is
known to possess SP1 and SP3 binding sites (Ihn and Tro-
janowska, 1997), whereas the OCN promoter is regulated
by AP-1–related proteins and, interestingly, by the Osf2/
Cbfa1 transcription factor (Frendo et al., 1998; Stein,
1997). Therefore, it is possible that the concomitant upreg-
ulation of expression of these genes in a condition of Src
deficiency does not necessarily imply a direct relationship
with Src, but rather an indirect regulation by Src-depen-
dent intracellular signaling events.
Our results indicate that the modifications induced by
Src deficiency in osteoblasts lead to the deposition of a ma-
trix capable of greater and/or faster mineralization. Bone
matrix is a mixture of extracellular proteins arranged to
promote mineral deposition. Particular interest has been
recently focused on osteopontin, whose expression has
been found to be increased in ia (incisor absent), op (osteo-
petrotic), and tl (toothless) osteopetrotic rats (Shalhoub et
al., 1994; Marks et al., 1989), but reduced in mouse Src2/2
fibroblasts (Chackalaparampil et al., 1996). Osteopontin is
a sialoprotein of bone necessary for osteoclast attachment
and bone resorption (Duong and Rodan, 1998), which sig-
nals the cell through the vitronectin receptors inducing
changes in cytosolic free-calcium concentration and phos-
phorylation patterns (Duong and Rodan, 1998). The os-
teopontin gene promoter has a CCAAT box, located at
253 to 2122 from the transcription start site, functioning
as a v-Src response element; v-Src stimulates osteopontin
expression in NIH 3T3 fibroblasts (Tezuka et al., 1996).
However, Chackalaparampil et al. (1996) showed that in in
vivo assays normal levels of osteopontin accumulated in
the bone matrix of Src2/2 mice. Despite the increased de-
position and mineralization of matrix in Src2/2 cultures, we
could not detect changes in osteopontin expression in os-
teoblasts treated with the AS-src or in primary and immor-
talized osteoblasts derived from the Src-deficient mice.
In conclusion, our study provides evidence that Src-defi-
cient osteoblasts exhibit a cell autonomous alteration that
lead to increased osteoblast numbers and bone formation
in vivo, as well as accelerated differentiation, and in-
creased matrix production, and/or mineralization in vitro.
These alterations contribute to the development of the os-
teopetrotic phenotype observed in Src-deleted mice. Thus,
Src exerts a negative regulatory influence on osteoblasts
and bone formation in normal cells.
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